The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU

María Chaparro, María G Donday, Francisco Abad-Santos, Francisco Javier Martín de Carpi, Miguel Ángel Maciá-Martínez, Dolores Montero, Diana Acosta, Yanire Brenes, Javier P Gisbert, María Chaparro, María G Donday, Francisco Abad-Santos, Francisco Javier Martín de Carpi, Miguel Ángel Maciá-Martínez, Dolores Montero, Diana Acosta, Yanire Brenes, Javier P Gisbert

Abstract

Background: Active disease during conception and pregnancy in women with inflammatory bowel disease (IBD) increases the risk of pregnancy complications and adverse neonatal outcomes. The use of IBD treatments during pregnancy should be weighed against their adverse effects on the neonate, but longer-term safety data and data on serious infection rates and malignancies postnatally are lacking, particularly for newer drugs, such as tofacitinib, vedolizumab and ustekinumab.

Methods: This ongoing, prospective registry study being conducted at 70 centres in Spain is enrolling pregnant women who are ⩾18 years, are at any point in pregnancy up to the end of the second trimester and have a diagnosis of Crohn's disease, ulcerative colitis or unclassified IBD. Patients will receive treatment decided independently by their IBD specialist. Each incident gestation will be followed up through pregnancy and the first 4 years postnatally. Three cohorts will be compared: biologicals exposed, immunomodulatory exposed and non-exposed. The primary endpoint is the risk of severe infection in newborns postnatally up to 4 years of age; other endpoints include serious adverse events (SAEs) such as pregnancy and delivery complications, neonatal SAEs, development [Ages and Stages Questionnaire-3 (ASQ3)], and malignancy incidence, up to 4 years of age. IBD specialists will collect maternal data (baseline/end of each trimester/1 month post-delivery), neonatal birth data, and the SAE and ASQ3 data in children exposed during pregnancy, reported every 3 months by the mother. Statistical analysis will include summary statistics for quantitative variables, comparisons of qualitative variables with significance set at p < 0.025 and a binary logistic regression model to determine the risk factors for severe infections.

Results: Enrolment began in September 2019 and study completion is expected in September 2028.

Conclusions: This prospective, controlled study will provide evidence on the long-term safety profile in children after intrauterine and lactation exposure to biological and immunomodulatory IBD treatments, including data on postnatal severe infections, development and malignancies.

Clinicaltrialsgov identifier: NCT03894228.

Keywords: anti-TNF; biological agents; breastfeeding; immunosuppressants; inflammatory bowel disease; pregnancy; tofacitinib; ustekinumab; vedolizumab.

Conflict of interest statement

Conflict of interest statement: MCh has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr Falk, Pharma, Tillotts Pharma. FAS has been consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Cinfa, FAES, Farmalíder, Ferrer, GlaxoSmithKline, Galenicum, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Silverpharma, Teva and Zambon. JPG has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Vifor Pharma.

© The Author(s), 2021.

References

    1. Gisbert JP, Chaparro M. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review. Drugs 2020; 80: 1085–1100.
    1. Aboubakr A, Riggs AR, Jimenez D, et al.. Identifying patient priorities for preconception and pregnancy counseling in IBD. Dig Dis Sci. Epub ahead of print 20 July 2020. DOI: 10.1007/s10620-020-06480-3.
    1. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010; 16: 881–895.
    1. Nielsen OH, Andreasson B, Bondesen S, et al.. Pregnancy in Crohn’s disease. Scand J Gastroenterol 1984; 19: 724–732.
    1. Nielsen OH, Andreasson B, Bondesen S, et al.. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735–742.
    1. Leung KK, Tandon P, Govardhanam V, et al.. The risk of adverse neonatal outcomes with maternal inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2021; 27: 550–562.
    1. Bortoli A, Pedersen N, Duricova D, et al.. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003–2006. Aliment Pharmacol Ther 2011; 34: 724–734.
    1. Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986; 79: 221–225.
    1. Oron G, Yogev Y, Shcolnick S, et al.. Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain. J Matern Fetal Neonatal Med 2012; 25: 2256–2260.
    1. Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 460–466.
    1. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 1426–1438.
    1. Lamb CA, Kennedy NA, Raine T, et al.. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68: s1–s106.
    1. Van der Woude CJ, Ardizzone S, Bengtson MB, et al.. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9: 107–124.
    1. Mahadevan U, Robinson C, Bernasko N, et al.. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Am J Obstet Gynecol 2019; 220: 308–323.
    1. Silverberg MS, Satsangi J, Ahmad T, et al.. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl. A): 5A–36A.
    1. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1: 514.
    1. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625–1629.
    1. Nguyen GC, Seow CH, Maxwell C, et al.. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016; 150: 734–757.e1.
    1. Boyd HA, Basit S, Harpsoe MC, et al.. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS One 2015; 10: e0129567.
    1. Harris PA, Taylor R, Thielke R, et al.. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.
    1. Chaparro M, Verreth A, Lobaton T, et al.. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol 2018; 113: 396–403.
    1. Casanova MJ, Chaparro M, Domenech E, et al.. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433–440.
    1. Kanis SL, de Lima-Karagiannis A, De Boer NKH, et al. Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study. Clin Gastroenterol Hepatol 2017; 15: 1232–1241.e1.
    1. de Meij TG, Jharap B, Kneepkens CM, et al.. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 38–43.
    1. Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opin Drug Saf 2014; 13: 1749–1762.
    1. Shihab Z, Yeomans ND, De Cruz P. Anti-tumour necrosis factor α therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohns Colitis 2016; 10: 979–988.
    1. Mahadevan U, Martin CF, Sandler RS, et al.. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012; 142: S149.
    1. Bortlik M, Duricova D, Machkova N, et al.. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis 2014; 20: 495–501.
    1. Luu M, Benzenine E, Doret M, et al.. Continuous anti-TNFalpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance database (EVASION). Am J Gastroenterol 2018; 113: 1669–1677.
    1. Moens A, Van der Woude CJ, Julsgaard M, et al.. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 2020; 51: 129–138.
    1. Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al.. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol 2019; 114: 1172–1175.
    1. Mahadevan U, Vermeire S, Lasch K, et al.. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45: 941–950.
    1. Venturin C, Nancey S, Danion P, et al.. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol 2017; 17: 80.
    1. Cortes X, Borras-Blasco J, Antequera B, et al.. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther 2017; 42: 234–236.
    1. Galli-Novak E, Mook SC, Buning J, et al.. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol 2016; 30: e191–e192.
    1. Klenske E, Osaba L, Nagore D, et al.. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn’s disease. J Crohns Colitis 2019; 13: 267–269.
    1. Rowan CR, Cullen G, Mulcahy HE, et al.. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis 2018; 12: 376–378.
    1. Mahadevan U, Dubinsky MC, Su C, et al.. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis 2018; 24: 2494–2500.
    1. Euser AM, Zoccali C, Jager KJ, et al.. Cohort studies: prospective versus retrospective. Nephron Clin Pract 2009; 113: c214–c217.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir